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Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome:
a cortical variant
Aims: Since the first description of the classical presenta-
tion of progressive supranuclear palsy (PSP) in 1963, now
known as Richardson’s syndrome (PSP-RS), several dis-
tinct clinical syndromes have been associated with PSP-
tau pathology. Like other neurodegenerative disorders, the
severity and distribution of phosphorylated tau pathology
are closely associated with the clinical heterogeneity of
PSP variants. PSP with corticobasal syndrome presenta-
tion (PSP-CBS) was reported to have more tau load in the
mid-frontal and inferior-parietal cortices than in PSP-RS.
However, it is uncertain if differences exist in the distribu-
tion of tau pathology in other brain regions or if the
overall tau load is increased in the brains of PSP-CBS.
Methods: We sought to compare the clinical and patho-
logical features of PSP-CBS and PSP-RS including quanti-
tative assessment of tau load in 15 cortical, basal ganglia
and cerebellar regions. Results: In addition to the similar
age of onset and disease duration, we demonstrated that
the overall severity of tau pathology was the same
between PSP-CBS and PSP-RS. We identified that there
was a shift of tau burden towards the cortical regions
away from the basal ganglia; supporting the notion that
PSP-CBS is a ‘cortical’ PSP variant. PSP-CBS also had less
severe neuronal loss in the dorsolateral and ventrolateral
subregions of the substantia nigra and more severe micro-
glial response in the corticospinal tract than in PSP-RS;
however, neuronal loss in subthalamic nucleus was
equally severe in both groups. Conclusions: A better
understanding of the factors that influence the selective
pathological vulnerability in different PSP variants will
provide further insights into the neurodegenerative
process underlying tauopathies.
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Introduction
The classical presentation of progressive supranuclear
palsy (PSP), now known as Richardson’s syndrome
(PSP-RS), includes as cardinal features the early onset of
postural instability with falls backwards, vertical supranu-
clear gaze palsy (VSGP) including downgaze and frontal
subcortical cognitive impairment [1–3]. Other well-
recognized clinical variants of PSP are PSP-parkinsonism
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(PSP-P) [2,4], pure akinesia and gait freezing (PSP-PAGF)
[5,6], primary non-fluent aphasia (PSP-PNFA) [7–10],
behavioural variant of frontotemporal dementia (PSP-
bvFTD) [11] and corticobasal syndrome (PSP-CBS) [12].
Clinicopathological studies have since demonstrated a
close correlation between topographical severity of tau
pathology and clinical phenotypes of PSP. For instance,
severe tau pathology was identified in the inferior frontal
gyrus in PSP-PNFA [8] and frontal and temporal cortices in
PSP-bvFTD [13]. In contrast, cortical tau was found to be
very mild in the PSP-PAGF subtype [5,6]. Similar clinico-
pathological correlation was also identified in another
closely related 4-repeat (4R) tauopathy, corticobasal
degeneration (CBD) and its clinical phenotypes [14].
Corticobasal syndrome (CBS) describes progressive
clumsiness and loss of function of one hand due to
apraxia, an alien limb, cortical sensory loss, dystonia
and levodopa-unresponsive rigidity, and it was initially
described as the distinctive clinical presentation of CBD
[15,16]. Since its original description, multifarious other
pathologies have been linked to a CBS presentation
[7,17,18]. From the archives of the Queen Square Brain
Bank for Neurological Disorders (QSBB), we showed that
the most common underlying pathology for CBS is PSP (6
of 21) rather than CBD (5 of 21); however, only 4% of all
pathologically diagnosed PSP cases (n = 227) had a CBS
presentation (PSP-CBS) [17]. Previously, Tsuboi et al.
quantified tau load in four selected cortical regions includ-
ing cingulate gyrus, mid-frontal cortex, motor cortex and
inferior-parietal cortex in three PSP-CBS cases and eight
randomly chosen PSP-RS cases [12]. They reported an
increased tau pathology in the mid-frontal and inferior-
parietal cortices in PSP-CBS compared with PSP-RS and
concluded that the CBS presentation of PSP was either
caused by a concurrent cortical pathology from a second-
ary process such as Alzheimer’s disease or primary PSP
tau pathology involving the cortical regions [12]. Never-
theless, it is uncertain if differences exist in the distribu-
tion of tau pathology in other brain regions or if the
overall tau load is increased in the brains of PSP-CBS. It is
noteworthy that imaging studies have identified predomi-
nant focal grey matter loss on voxel-based morphometry
in premotor cortex, posterior superior frontal lobe and
supplementary motor area and relatively preserved brain
stem grey matter in cases with PSP-CBS [19]. We there-
fore hypothesized that the distribution of tau pathology in
PSP-CBS may resemble the distribution of grey matter loss
identified by in vivo imaging in voxel-based morphometry.
The aims of this study were: (i) to validate the findings
reported by Tsuboi et al. in a significantly larger cohort of
PSP-CBS cases and to quantitatively assess tau distribu-
tion in more cortical regions and other brain regions
including the basal ganglia, brainstem and cerebellum; (ii)
to determine the cellular lesions which contribute to the
tau pathology were characteristic of PSP pathology rather
than Alzheimer-type neurofibrillary tangle pathology;
and (iii) to assess neuronal loss of the substantia nigra and
subthalamic nuclei and pathological involvement of the
corticospinal tract.
Materials and methods
Cases
Of the 227 PSP cases available in the QSBB archives
between 1988 and 2010, nine had received a final clinical
diagnosis of CBS/CBD by a neurologist during life (PSP-
CBS, 3.9% of all PSP cases). An additional case, seen and
diagnosed pathologically at the University of Nottingham,
was also included. These 10 PSP-CBS cases were matched
with 10 PSP-RS control cases for disease duration and age
at death. The brain donor programme of the QSBB was
approved by a London Multi-Centre Research Ethics Com-
mittee and tissue is stored for research under a license
from the Human Tissue Authority.
Medical record review
Systematic retrospective review of the medical records
was carried out by one of us (H. L.). All patients were
assessed by at least one neurologist during life. Symp-
toms and clinical signs were recorded as being absent if
they were not reported in the case notes. When the onset
was not recorded, the onset was taken as the time when
the particular clinical feature was first mentioned in the
notes. If there were conflicting clinical features, the find-
ings of the neurologist took precedence. The definitions
for each selected clinical feature have been described pre-
viously [17].
Pathological material
The neuropathological diagnosis of PSP was confirmed in
all 20 cases (T. R. and J. L. H.). Immediately after post
mortem the brains were divided in the mid-sagittal plane.
One half, chosen randomly, was sliced and tissue blocks
were frozen and stored at -80°C, while the other half was
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immersed and fixed in 10% neutral formalin for 3 weeks
before neuropathological examination. Tissue blocks were
taken using standard protocols. Established pathological
diagnostic criteria for PSP were used, requiring the pres-
ence of neurofibrillary tangles (NFTs), neuropil threads
(NTs) and glial tau pathology in different brain regions
including the cerebral cortex, striatum, globus pallidus
(GP), subthalamic nucleus (STN), midbrain, pons and cer-
ebellum together with neuronal loss and gliosis in basal
ganglia and brainstem and cerebellar nuclei [20–23]. In
each case 8-mm-thick tissue sections cut from the paraffin
blocks and stained with haematoxylin and eosin (H&E)
were used to assess neuronal loss and gliosis in the basal
ganglia and substantia nigra. Immunohistochemistry
with antibodies to phosphorylated tau (AT8; BioScience
Life Sciences; 1:600), 3-repeat (3R) tau and 4R tau
(Upstate/Millipore; 3R tau: RD3; 1:2000; 4R tau: RD4;
1:200) [24], microglia (CD68; Dako; PG-M1; 1:75),
aB-crystallin (Novocastra; G2JF; 1:300), amyloid-b (Ab)
peptide (Dako; 6F/3D; 1:100) and a-synuclein (Vector
Laboratories; KM51; 1:50) was performed using a stand-
ard avidin-biotin method as previously described [25].
Additional pathologies were documented. Argyrophilic
grain disease was identified by AT8 and aB-crystallin
immunohistochemistry [26] while Ab cortical plaque
pathology was characterized using the modified CERAD
(Consortium to Establish a Registry for Alzheimer’s
disease) criteria [27]. Alzheimer’s type NFT pathology was
determined using AT8 immunohistochemistry for Braak
and Braak staging [28]. The presence of incidental Lewy
body disease [29], cerebrovascular disease [30] and cer-
ebral amyloid angiopathy (CAA) [31] was documented.
Only cases with limited Alzheimer-type neurofibrillary
tangle pathology of Braak and Braak stage III or less were
recruited to avoid confounding the analysis of PSP-related
tau pathology.
Regional tau quantification with image analysis
Using coded slides, quantitative assessment of tau pathol-
ogy, comprising all tau-positive structures including NFTs,
pretangles (PreTs) NTs, tufted astrocytes (TAs) and coiled
bodies (CBs) was performed by one rater (H. L.). Fifteen
brain regions, which are known to be affected in PSP and
whose involvement is predicted to contribute to the clini-
cal features, were selected; the posterior frontal cortex
including the motor strip, cerebral cortex and subcortical
white matter of the middle frontal gyrus (level: 1 cm
behind the temporal pole), middle temporal gyrus (level:
mammillary body) and parietal region (level: 1 cm behind
the splenium), caudate nucleus, putamen, GP, STN, sub-
stantia nigra (SN; level: emergence of the third cranial
nerve), pontine base, including the pontine nuclei, cer-
ebellar dentate nucleus and cerebellar white matter. The
posterior frontal white matter was omitted from the analy-
sis as the quantity was very small in some cases due to
variability of routine sampling. In each region, the images
of 10 random microscopic fields using a ¥20 objective
were captured by a colour digital camera connected to the
microscope (Nikon Microphot-FXA and Digit sight DS-L1)
and processed with an image analysis software (Image-
Pro; Media Cybernetics, Inc., Roper Industries, Rockville,
USA), converted to grey-scale images and labelling was
measured in pixels. Threshold was adjusted to capture the
two-dimensional area of all tau-positive lesions and the
same threshold setting was used throughout the study.
‘Areal fraction’, defined by a ratio of the tau-positive
immunoreactive pixels to the total number of pixels of the
whole field was computed by Image Pro and tau load for
each region, that is, ‘regional’ tau load was expressed as
percentage (areal fraction ¥ 100%) [32]. ‘Total’ tau load
was the sum of tau load in all 15 regions. ‘Cortical’ tau
load was the sum of tau load in seven regions, comprised
of both grey and subcortical white matter in the anterior
frontal, temporal and parietal regions and grey matter in
the posterior frontal region. ‘Basal ganglia’ tau load was
the sum of tau load in four structures: caudate nucleus,
putamen, GP and STN.
Quantification of tau-positive cellular lesions
The different tau-positive cellular lesions were quantified
individually in 10 random fields of three selected regions
(posterior frontal cortex, anterior frontal cortex and
caudate), where differences in regional tau load were
found to be the most robust between PSP-RS and PSP-
CBS. NFTs, PreTs, TAs and CBs were individually counted.
NT pathology was quantified using a four-tiered semi-
quantitative grading scale (0–3, with grade 0 = no NT to
grade 3 = most severe NT).
Neuronal loss in the subthalamic nucleus and
substantia nigra
Neuronal loss in STN and SN were determined using a
four-tiered semi-quantitative grading system by a neu-
ropathologist (T. R.), blinded to the clinical features (0–3,
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with grade 0 = no neuronal loss to grade 3 = most severe
neuronal loss). SN was divided into five regions (medial,
dorsomedial, dorsolateral, ventrolateral and lateral).
Corticospinal tract involvement
Microglial pathology of the corticospinal tract (CST) iden-
tified in the midbrain cerebral peduncles was assessed
using CD68 immunohistochemistry by two neuropatholo-
gists (T. R. and J. H.) blinded to the clinical features. A
semi-quantitative grade was established by consensus
(grade 0 = baseline microglial population to grade
3 = most severe microglial pathology).
Tau biochemistry
Frontal cerebral cortex was used for tau biochemistry in
two PSP-CBS, two PSP-RS cases and two pathologically
diagnosed CBD cases with classical CBS presentation
(CBD-CBS), which were randomly selected. Regional vari-
ation of phosphorylated tau species in PSP brains was
previously reported [33]. However, tau protein extraction
was limited to the frontal cortex in the present study.
Sarkosyl-insoluble tau isolation Isolation of sarkosyl-
insoluble tau was carried out as previously described
[34,35]. Brain tissue was homogenized in 10¥ volume
(v/w) homogenization buffer (10 mM Tris–HCl pH 7.4,
0.8 M NaCl, 1 mM EGTA and 10% sucrose containing
Complete protease inhibitor cocktail (Roche, Burgess Hill,
UK). The suspension was then spun at 20 000 g for
20 min at 4°C and the supernatant set aside. The pellet
was re-suspended in 5¥ volumes of homogenization buffer
and re-centrifuged as above. The supernatants were com-
bined and N-lauryl sarcosinate added to a concentration of
1% (w/v), and incubated at room temperature for 1 h with
shaking. The mixture was then centrifuged at 100 000 g
for 1 h at 4°C. The sarkosyl-insoluble pellet was re-
suspended in 50 mM Tris–HCl pH 7.5 at 0.2 ml/g of
starting material.
SDS-PAGE Sarkosyl-insoluble tau was separated on 10%
SDS-polyacrylamide gels and blotted onto nitrocellulose
membranes using standard procedures. The blots were
probed with a pan-tau rabbit polyclonal TP70 antibody
that recognizes the carboxy-terminus of tau [36,37]
(1/15 000; kind gift from Dr Diane Hanger, King’s College,
London) and IRDye 800CW Donkey Anti-Rabbit second-
ary antibody (Li-Cor Biosciences) followed by imaging on a
Li-Cor Odyssey Infrared Scanner.
Haplotype analysis of theMAPT gene
Haplotype was determined by PCR (polymerase chain
reaction) typing of the 238 bp MAPT H2 deletion in
intron nine in 17 cases (8 PSP-CBS, 9 PSP-RS) where
frozen tissue was available for DNA extraction [38,39].
Statistical analysis
The Mann–Whitney U-Test was used to compare tau load
between PSP-CBS and PSP-RS. The null hypothesis (H0)
was rejected if the P value was <0.05 when ‘total’, ‘corti-
cal’ and ‘basal ganglia’ tau load was assessed. For
‘regional’ tau load assessment, P value of 0.0033 (0.05/
15) was used to adjust for multiple comparisons; for tau-
positive cellular lesion load, P value of 0.01 (5 different
types of tau lesions: 0.05/5) was used. c2/Fisher’s exact
test or the Student’s t-test was used to compare semi-
quantitative grading or clinical data using P value of
0.05. The intra-rater repeatability was assessed by repeat-
ing tau quantification in four randomly selected cases
(20%). The intraclass correlation coefficient was 0.80
(P < 0.001), indicating that the ‘regional’ tau load results
were highly repeatable. The spss 17.0 program (IBM Cor-
poration, New York, USA) was used for statistical analysis.
Results
Clinical features
PSP-CBS (Tables 1a and 2) All patients had been diag-
nosed with CBS/CBD by neurologists during life. Mean
duration of first symptom onset to the final clinical diag-
nosis was 3.4 years. All cases had strikingly asymmetrical
clinical features throughout the entire disease course; 10
had ideomotor limb apraxia, eight had hand dystonia, five
had focal distal myoclonus, three had an alien limb phe-
nomenon, three had non-fluent aphasia, three had corti-
cal sensory loss and wo had hemisensory neglect. Delayed
initiation of horizontal saccades was observed in three
patients, two of whom also had head thrust at saccadic
initiation (cases 2 & 5).
Seven patients developed ocular features suggestive of
PSP including slow vertical saccades or VSGP but in most
152 H. Ling et al.
NAN 2014; 40: 149–163© 2013 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
Ta
b
le
1a
.
D
em
og
ra
ph
ic
,c
lin
ic
al
an
d
ge
n
et
ic
h
ap
lo
ty
pe
da
ta
of
P
SP
-C
B
S
pa
ti
en
ts
P
SP
-C
B
S
C
as
e
n
o.
1
2
3
4
5
6
7
8
9
1
0
G
en
de
r
M
F
M
M
M
F
F
F
M
F
A
ge
at
on
se
t
(y
r)
5
5
6
3
.8
6
0
.4
6
0
.5
7
9
.3
6
6
.3
6
0
6
4
7
7
7
3
A
ge
at
de
at
h
(y
r)
6
4
.3
7
0
.2
6
6
.3
6
8
.8
8
2
.8
7
7
.9
7
0
.8
7
2
.5
8
1
7
9
.2
D
is
ea
se
du
ra
ti
on
(y
r)
9
.3
6
.4
5
.9
8
.3
3
.5
1
1
.6
1
0
.8
8
.5
4
6
.2
In
it
ia
lc
lin
ic
al
D
x
P
D
C
B
S
C
.S
po
n
d.
C
V
D
P
D
D
ep
re
ss
io
n
C
B
S
P
SP
P
SP
C
B
S
Fi
n
al
cl
in
ic
al
D
x
C
B
S
C
B
S
C
B
S
C
B
S
C
B
S
C
B
S
C
B
S
C
B
S
C
B
S
C
B
S
D
u
ra
ti
on
fr
om
on
se
t
to
fin
al
D
x
(y
r)
6
.3
3
.5
5
.2
2
.1
1
.5
2
.6
7
6
4
3
In
it
ia
ls
ym
pt
om
(s
)
B
al
an
ce
di
ffi
cu
lt
y
C
lu
m
sy
u
se
le
ss
ar
m
C
lu
m
sy
u
se
le
ss
ar
m
Je
rk
y
ar
m
Fa
lls
G
ai
t
di
ffi
cu
lt
y
&
co
gn
it
iv
e
sl
ow
in
g
C
lu
m
sy
u
se
le
ss
ar
m
&
ba
la
n
ce
di
ffi
cu
lt
y
Fa
lls
B
al
an
ce
di
ffi
cu
lt
y
&
sl
u
rr
ed
sp
ee
ch
C
lu
m
sy
u
se
le
ss
ar
m
&
fa
lls
A
sy
m
m
et
ri
ca
lf
ea
tu
re
s
+
+
+
+
+
+
+
+
+
+
Li
m
b
ap
ra
xi
a
+
+
+
+
+
+
+
+
+
+
A
lie
n
lim
b
-
+
-
-
-
-
-
-
+
+
C
or
ti
ca
ls
en
so
ry
lo
ss
-
+
+
-
-
-
-
-
-
-
H
em
i-
n
eg
le
ct
-
+
-
-
-
-
-
+
-
-
A
ph
as
ia
-
+
-
-
-
+
-
-
+
-
H
an
d
dy
st
on
ia
+
+
+
+
-
-
+
+
+
+
C
le
n
ch
ed
fis
t
+
+
+
+
-
-
+
-
+
+
M
yo
cl
on
u
s
-
-
+
+
+
-
+
-
+
-
T
re
m
or
-
-
-
-
+
-
-
-
+
-
D
el
ay
ed
in
it
ia
ti
on
of
sa
cc
ad
es
N
K
+
N
K
+
+
N
K
N
K
-
-
N
K
Sl
ow
ve
rt
ic
al
sa
cc
ad
es
N
K
-
N
K
+
+
+
N
K
+
N
K
+
V
SG
P
+
-
N
K
-
+
+
N
K
+
+
-
Po
st
u
ra
li
n
st
ab
ili
ty
/f
al
ls
w
it
h
in
1
st
yr
-
+
-
-
+
+
-
+
+
+
C
og
n
it
iv
e
de
cl
in
e
-
+
-
+
+
+
-
+
-
+
Pe
rs
on
al
it
y
ch
an
ge
/a
pa
th
y
-
-
-
+
-
+
-
-
-
-
P
yr
am
id
al
si
gn
s
+
+
-
+
+
-
+
-
-
-
A
ki
n
et
ic
ri
gi
di
ty
in
fir
st
2
yr
s
+
-
-
-
+
+
-
+
+
+
D
ys
ar
th
ri
a
in
fir
st
2
yr
s
+
-
-
+
-
-
-
-
+
-
D
ys
ph
ag
ia
in
fir
st
2
yr
s
-
-
-
N
K
-
-
N
K
N
K
+
-
Le
vo
do
pa
re
sp
on
se
-
-
-
-
M
ild
-
-
-
-
M
ild
H
1
/H
2
H
ap
lo
ty
pe
H
1
/H
1
H
1
/H
1
H
1
/H
1
N
K
H
1
/H
1
H
1
/H
2
H
1
/H
1
H
1
/H
1
N
K
H
1
/H
2
PSP presenting with CBS 153
NAN 2014; 40: 149–163© 2013 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
Ta
b
le
1b
.
D
em
og
ra
ph
ic
,c
lin
ic
al
an
d
ge
n
et
ic
h
ap
lo
ty
pe
da
ta
of
P
SP
-R
S
pa
ti
en
ts
P
SP
-R
S
C
as
e
n
o.
1
1
1
2
1
3
1
4
1
5
1
6
1
7
1
8
1
9
2
0
G
en
de
r
F
F
M
M
F
M
M
F
F
M
A
ge
at
on
se
t
(y
r)
6
2
6
5
.2
6
3
7
4
.3
6
6
6
1
5
2
.1
6
7
7
2
7
6
A
ge
at
de
at
h
(y
r)
6
9
.8
7
1
.3
6
9
.5
7
9
.5
8
1
.7
7
8
.3
6
1
.3
7
3
7
9
.1
8
0
.7
D
is
ea
se
du
ra
ti
on
(y
r)
7
.8
6
.1
6
.5
5
.2
1
5
.7
1
7
.3
9
.2
6
7
.1
4
.7
In
it
ia
lc
lin
ic
al
D
x
D
ep
re
ss
io
n
P
D
D
ep
re
ss
io
n
P
D
P
D
C
V
D
P
SP
P
SP
P
SP
P
SP
Fi
n
al
cl
in
ic
al
D
x
P
SP
P
SP
P
SP
P
SP
P
SP
P
SP
P
SP
P
SP
P
SP
P
SP
D
u
ra
ti
on
fr
om
on
se
t
to
fin
al
D
x
(y
r)
4
4
2
.5
3
7
2
.2
3
3
3
2
In
it
ia
ls
ym
pt
om
(s
)
Fa
lls
&
co
gn
it
iv
e
sl
ow
in
g
Fa
lls
Fa
lls
&
co
gn
it
iv
e
sl
ow
in
g
Fa
lls
Sl
ow
u
p
Sl
u
rr
ed
sp
ee
ch
B
al
an
ce
di
ffi
cu
lt
y
Fa
lls
Fa
lls
Fa
lls
A
sy
m
m
et
ri
ca
lf
ea
tu
re
s
-
-
-
-
-
-
-
-
-
-
Li
m
b
ap
ra
xi
a
-
-
-
-
-
-
-
-
-
-
A
lie
n
lim
b
-
-
-
-
-
-
-
-
-
-
C
or
ti
ca
ls
en
so
ry
lo
ss
-
-
-
-
-
-
-
-
-
-
H
em
in
eg
le
c
-
-
-
-
-
-
-
-
-
-
A
ph
as
ia
-
-
-
-
-
-
-
-
-
-
H
an
d
dy
st
on
ia
-
-
-
-
-
-
+
-
-
-
C
le
n
ch
ed
fis
t
-
-
-
-
-
-
-
-
-
-
M
yo
cl
on
u
s
-
-
-
-
-
-
-
-
-
-
T
re
m
or
+
-
-
-
-
-
-
-
-
+
D
el
ay
ed
in
it
ia
ti
on
of
sa
cc
ad
es
N
K
-
-
N
K
-
-
-
-
-
N
K
Sl
ow
ve
rt
ic
al
sa
cc
ad
es
+
N
K
+
N
K
+
+
N
K
+
+
N
K
V
SG
P
+
+
+
+
+
+
+
+
+
+
Po
st
u
ra
li
n
st
ab
ili
ty
/f
al
ls
w
it
h
in
1
st
yr
+
+
+
+
+
+
+
+
+
+
C
og
n
it
iv
e
de
cl
in
e
+
-
+
-
-
-
-
+
-
-
Pe
rs
on
al
it
y
ch
an
ge
/a
pa
th
y
+
-
+
+
-
-
+
+
-
-
P
yr
am
id
al
si
gn
s
-
-
-
-
-
-
-
-
-
-
Ea
rl
y
ak
in
et
ic
ri
gi
di
ty
in
fir
st
2
yr
s
+
+
+
+
+
+
+
+
+
+
Ea
rl
y
dy
sa
rt
h
ri
a
in
fir
st
2
yr
s
+
N
K
-
-
-
+
+
N
K
+
-
Ea
rl
y
dy
sp
h
ag
ia
in
fir
st
2
yr
s
+
-
-
-
-
-
+
N
K
+
-
Le
vo
do
pa
re
sp
on
se
-
-
-
-
-
-
-
-
-
-
H
1
/H
2
H
ap
lo
ty
pe
H
1
/H
1
H
1
/H
1
N
K
H
1
/H
1
H
1
/H
1
H
1
/H
1
H
1
/H
1
H
1
/H
1
H
1
/H
1
H
1
/H
1
C
B
S,
co
rt
ic
ob
as
al
sy
n
dr
om
e;
C
.S
po
n
d,
ce
rv
ic
al
sp
on
dy
lo
si
s;
C
V
D
,c
er
eb
ro
va
sc
u
la
r
di
se
as
e;
D
x,
di
ag
n
os
is
;F
,f
em
al
e;
M
,m
al
e;
N
A
,n
ot
ap
pl
ic
ab
le
;N
K
,n
ot
kn
ow
n
;P
D
,P
ar
ki
n
so
n
’s
di
se
as
e;
P
SP
,p
ro
gr
es
si
ve
su
pr
an
u
cl
ea
r
pa
ls
y,
R
S,
R
ic
h
ar
ds
on
’s
sy
n
dr
om
e;
V
SG
P,
ve
rt
ic
al
su
pr
an
u
cl
ea
r
ga
ze
pa
ls
y;
yr
,y
ea
r.
154 H. Ling et al.
NAN 2014; 40: 149–163© 2013 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
cases these occurred in the advanced stage of the illness.
Two exceptions were cases 8 and 9 who developed VSGP
within 4 years from symptom onset and an initial clinical
diagnosis of PSP was considered, but was later revised to
CBS after the onset of asymmetrical cortical symptoms.
Six patients developed postural instability or falls within
the first year of symptom onset. Nevertheless, VSGP (c2,
P = 0.016) and postural instability or early falls were still
more frequent in PSP-RS than in PSP-CBS. Pyramidal signs
were more frequent in PSP-CBS (n = 5) than in PSP-RS
(n = 0) (c2, P = 0.016). Extensor plantars and hyper-
reflexia were noted in five PSP-CBS patients, three of whom
also had spasticity and one had pyramidal weakness, but
none of these features was observed in PSP-RS.
PSP-RS (Tables 1b and 2) All PSP-RS patients had a final
clinical diagnosis of probable PSP and had VSGP includ-
ing downgaze abnormalities and early postural instability
or falls. Three patients had cognitive decline and five had
frontal type personality change characterized by apathy
and abulia.
Pathological findings and clinicopathological
correlations
Both PSP-CBS and PSP-RS groups met established patho-
logical criteria of PSP [20–22]. All inclusion types were
immunoreactive for 4R tau by differential immunohisto-
chemistry but negative for 3R tau in all cases [24], which
was an expected finding for PSP.
‘Regional’ tau load The median ‘regional’ tau load in the
posterior frontal cortical grey matter (PSP-CBS: 0.59; PSP-
RS: 0.05), anterior frontal cortical grey matter (PSP-CBS:
0.06; PSP-RS: 0.03) and parietal subcortical white matter
(PSP-CBS: 0.06; PSP-RS: 0.01) was significantly greater in
PSP-CBS than in PSP-RS (P < 0.0033 in all). The median
‘regional’ tau load in the caudate (PSP-CBS: 0.14; PSP-RS:
0.49; P < 0.001), STN (PSP-CBS: 0.21; PSP-RS: 0.40;
P < 0.001) and cerebellar white matter (PSP-CBS: 0.02;
PSP-RS: 0.06; P = 0.007 with borderline significance) was
greater in the PSP-RS than in PSP-CBS (Figures 1 and 2).
The presence of delayed initiation of horizontal sac-
cades in PSP-CBS had a moderate correlation with an
increased total parietal ‘tau load’ (Spearman’s correlation
coefficient = 0.59; P < 0.001). However, other cortical
features such as cortical sensory loss, alien limb phenom-
enon or hemi-sensory neglect did not correlate with the
parietal ‘tau load’ (P > 0.05) or other ‘regional tau load’.
‘Total’, ‘cortical’ and ‘basal ganglia’ tau load
(Figure 3) There was no difference in ‘total’ tau load
between the PSP-CBS and PSP-RS groups (P = 0.176,
Figure 3). However, PSP-CBS had an increased ‘cortical’
tau load when compared with PSP-RS (P < 0.001); and
the ‘basal ganglia’ tau load was greater in PSP-RS than in
PSP-CBS (P = 0.003).
In five PSP-CBS cases, the half brains examined were
contralateral to the side with the more predominant clini-
cal symptoms and signs. The median ‘total’ and ‘cortical’
tau load were numerically, but not statistically, greater
in these five cases (total tau load = 5.3; cortical tau
Table 2. Demographic features between PSP-CBS and PSP-RS
PSP-CBS PSP-RS
P values
(Student’s
t-test)
(mean years  SD)
Mean age of symptom onset 65.9  8.0 65.9  7.1 0.98
Mean age of death 73.4  6.4 74.4  6.5 0.72
Mean disease duration 7.5  2.7 8.6  4.4 0.51
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Figure 1. Quantitative data illustrating median regional tau load
in PSP-RS (black) and PSP-CBS (yellow) in 15 selected regions.
Error bars represent 95% confidence interval. *Represents
statistical significance, P < 0.0033 using the Mann–Whitney
U-Test. PFG, posterior frontal grey matter; AFG, anterior frontal
grey matter; AFWM, anterior frontal white matter; TG, temporal
grey matter; TWM, temporal white matter; PG, parietal grey
matter; PWM, parietal white matter; SN, substantia nigra; PONS,
pons; CAUD, caudate; PUT, putamen; GP, globus pallidus; STN,
subthalamic nucleus; DENT, dentate nucleus; CWM, cerebellar
white matter.
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Figure 2. Tau immunohistochemistry in selected brain regions of the two most representative cases. PSP-CBS has significantly greater tau
load in the posterior frontal (A) and anterior frontal grey matter (C) when compared with PSP-RS (B, D). Regional tau load in the caudate
and subthalamic nucleus are greater in PSP-RS (F, H) than in PSP-CBS (E, G). Median tau load values. Posterior frontal grey matter:
(A) PSP-CBS: 1.09; (B) PSP-RS: 0.05; Anterior frontal grey matter: (C) PSP-CBS: 0.18; (D) PSP-RS: 0.04; Caudate: (E) PSP-CBS: 0.11;
(F) PSP-RS: 1.06; Subthalamic nucleus: (G) PSP-CBS: 0.05; (H) PSP-RS: 0.29. Tau load for each region, that is, ‘regional’ tau load was
expressed as percentage (areal fraction ¥ 100%); ‘areal fraction’, which was computed by Image Pro, was defined by a ratio of the
tau-positive immunoreactive pixels to the total number of pixels of the whole field. AT8 immunohistochemistry, bar in panel B represents
225 microns in all the panels.
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load = 1.4) compared with the remaining PSP-CBS cases
(total tau load = 4.0; cortical tau load = 1.0).
Tau-positive cellular lesions In the posterior frontal corti-
cal grey matter, all types of tau lesions were more numer-
ous in PSP-CBS than in PSP-RS (NFTs, TAs, CBs and NTs:
P < 0.001; PreTs: P = 0.005). In the anterior frontal grey
matter, there were numerically, but not statistically, more
NFTs, CBs and NTs in PSP-CBS than in PSP-RS (P > 0.01
in all). In the caudate, there were more TAs, NTs, and
NFTs, in PSP-RS than in PSP-CBS (TAs and NTs:
P < 0.001, NFTs: P = 0.01).
Neuronal loss In the STN, the median semi-quantitative
rating score for neuronal loss was moderate (grade 2) and
there was no difference between the two groups (c2;
P  0.05). In the SN, neuronal loss was more severe in
the dorsolateral (c2; P = 0.033) and ventrolateral (c2;
P = 0.018) subregions in PSP-RS than in PSP-CBS
(Figure 4).
CST involvement There was a more severe microglial
response in the CST in PSP-CBS, ranged from mild to
severe, than in PSP-RS, in which CST involvement was
very mild (c2; P = 0.035) (Figure 5).
Additional pathological findings The CERAD Ab plaque
score ranged from ‘absent’ to ‘sparse’, except for two PSP-
CBS and one PSP-RS cases, which had a ‘moderate’ score
[27]. Small vessel cerebrovascular disease was noted in
one PSP-CBS and one PSP-RS case. Other additional
pathological findings are summarized in Table 3.
Tau biochemistry and haplotype analysis
Western blots of the sarkosyl-insoluble tau fractions from
the frontal cortical homogenates showed the characteris-
tic doublet at 64 and 68 kDa indicating predominant 4R
tau in PSP-CBS, PSP-RS and CBD-CBS cases (Figure 6).
Our PSP-CBS and PSP-RS cases showed a single band at
approximately 33 kDa, whereas the CBD-CBS cases had a
doublet at approximately 37 kDa (Figure 6), which are
consistent with previous findings on the molecular differ-
ences in the low molecular weight proteolytic fragments
between CBD and PSP [14,40]. There was no significant
association between H1/H1 or H1/H2 genotype with
either of the PSP subgroups (c2 test; P = 0.21, Table 1).
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Figure 3. The median ‘total tau load’ between the PSP-CBS and
PSP-RS groups are the same. However, the PSP-CBS group has
greater median ‘cortical tau load’ and less ‘basal ganglia tau load’
than the PSP-RS group (Mann–Whitney U-Test). ‘Cortical tau load’
is the sum of regional tau load of posterior frontal grey matter,
anterior frontal grey and white matter, temporal grey and white
matter, parietal grey and white matter. ‘Basal ganglia tau load’ is
the sum of regional tau load of caudate, putamen, globus pallidus
and subthalamic nucleus. ‘Total tau load’ is the sum of regional
tau load of all 15 brain regions. Error bars represent 95%
confidence interval.
Figure 4. PSP-RS (B) has greater degree of neuronal loss in the ventrolateral (arrows) and dorsolateral substantia nigra than in PSP-CBS
(A). Haematoxylin and eosin method, bar in panel B represents 1135 microns in both panels.
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Discussion
We compared the morphological, biochemical and genetic
characteristics of 10 clinically well-characterized PSP-
CBS cases and 10 age- and disease duration-matched
PSP-RS controls. Irrespective of the clinical presentation,
all our cases met established neuropathological diagnostic
criteria of PSP with the presence of 4R tau-positive neu-
ronal and glial inclusions, including TAs in a characteris-
tic distribution [20–22]. Our biochemical studies of
sarcosyl insoluble tau also confirmed 4R tau as the main
protein species in both PSP-RS and PSP-CBS groups
and the presence of a smaller, faster migrating carboxy-
terminal fragment as previously reported in PSP [40,41].
We found no difference in the distribution of the H1/H1
and H1/H2 haplotypes between the two PSP groups.
We used morphometry to compare tau load, defined as
the sum of all tau positive lesions in the brain regions
studied, between the two PSP groups and to determine
the contribution of different neuronal and glial lesions to
the tau pathology. A previous study at the Mayo Clinic
established that PSP-CBS was associated with a greater
tau burden in the mid-frontal and inferior-parietal corti-
Table 3. Additional pathological findings of PSP-CBS and PSP-RS groups
PSP-CBS PSP-RS
CERAD neuritic plaque score
Negative 1 1
Infrequent 7 8
Moderate 2 (cases 5 & 7) 1 (case 15)
Frequent 0 0
Tau-positive AGD 4 (cases 3, 5, 8, 9) 4 (cases 11, 14, 16, 18)
Incidental Lewy body disease 1 (Braak stage 3) 0
Cerebrovascular pathology 1 (mild) 1 (severe, case 19)
Cerebral amyloid angiopathy 1 (mild) 0
AGD, argyrophilic grain disease; CERAD, Consortium to Establish a Registry for Alzheimer’s disease.
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Figure 5. A more severe microglial pathology in the corticospinal
tract was identified in PSP-CBS when compared with PSP-RS
(c2; P = 0.035). A semi-quantitative grading scale was used to
characterize the severity of microglial pathology; grade 0 = baseline
microglial population, grade 1 = mild microglial pathology; grade
2 = moderate microglial pathology; grade 3 = severe microglial
pathology.
Figure 6. Western blot analysis of sarkosyl-insoluble tau from
frontal cortex homogenates of CBD-CBS, PSP-CBS and PSP-RS. The
characteristic doublet of predominant 4R-tau pathology was
observed in both CBD and PSP cases (arrowheads). CBD-CBS cases
have a lower molecular weight doublet consisting of proteolytic
fragments at approximately 37 kDa (**); whereas PSP-RS and
PSP-CBS cases have a single band at approximately 33 kDa (*).
Numbers on the left indicate positions of molecular weight
markers (kDa).
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ces than in PSP-RS [12]. Here, by assessing a greater
number of cases and more brain regions, we validated
their findings by showing increased tau load in the cortical
regions predominantly in the posterior frontal grey
matter, anterior frontal grey matter and parietal white
matter in PSP-CBS. We also extended the quantitative tau
assessment to other non-cortical regions which enabled
us to identify a reduced tau load in the caudate, STN and
cerebellar white matter in the CBS variant. It is notewor-
thy that the increased cortical tau load is compensated by
the reduced basal ganglia tau load in PSP-CBS resulting in
the total tau load, determined as the sum of the all
regional tau load, being similar in the two PSP groups.
Increased cortical tau pathology has also been docu-
mented in PSP variants with cortical features including
‘atypical’ PSP with progressive apraxia of speech and
non-fluent aphasia [42], PSP-bvFTD [11,43], and,
together with PSP-CBS, these clinical phenotypes are col-
lectively referred as the ‘cortical’ PSP variants [44]. On the
other hand, PSP-P and PSP-PAGF, which are considered as
the ‘brainstem’ variants of PSP, have less severe overall tau
pathology when compared with PSP-RS [5,6]. Interest-
ingly, these ‘brainstem’ variants are associated with a
more benign disease course and a longer disease duration
compared with the classical PSP-RS [5,6,30]; whereas the
disease duration of our PSP-CBS group was similar to that
of PSP-RS group previously reported [2]. We speculate
that the total tau pathology may inversely correlate with
the disease duration in PSP variants and while the ‘brain-
stem’ PSP variant appears to be a more ‘benign’ form of
PSP, the ‘cortical’ PSP variant represents a deviation from
the classical presentation determined by a shift of tau
pathology from the basal ganglia to the cerebral cortex. By
selecting only cases with limited Alzheimer-type NFT
pathology and assessing coexisting secondary patholo-
gies, it is clear that the clinical presentation in our PSP-
CBS cases was closely associated with the topographical
severity of tau pathology which could not otherwise be
explained by secondary pathologies. We also demon-
strated that the regional differences in tau load between
the two PSP groups were contributed by neuronal and
glial lesions characteristic of PSP pathology rather than
Alzheimer-related tau pathology [45].
A recent detailed clinicopathological study from the
Mayo Clinic compared the characteristics of CBS and RS
clinical phenotypes in pathologically confirmed CBD cases
[14]. Their study on CBD also demonstrated significant
differences in the topographical severity of tau pathology
between the two CBD subtypes, which correlated with the
different clinical presentations. Similar to the findings in
our PSP-CBS cases, their study showed that the CBD-CBS
cases had more severe tau deposition in the cortical
regions and less severe tau pathology in the lower brain-
stem and cerebellum when compared with the CBD-RS
cases. However, total tau load and the contribution by
different neuronal and glial lesions to the tau pathology
were not assessed [14].
The STN is one of the regions characteristically targeted
by the PSP disease process [20,46] while this nucleus is
better preserved in cases with pathologically confirmed
CBD. In our PSP-CBS cases, the atrophy and neuronal loss
in the STN was as severe as in the PSP-RS cases, despite the
regional tau load of the STN being less in PSP-CBS than in
PSP-RS, indicating that glial, rather than neuronal tau,
might have significantly contributed to the differences in
tau load. It is noteworthy that a relatively milder tau
pathology in the STN has been documented in other PSP
variants such as ‘atypical’ PSP with progressive apraxia of
speech and non-fluent aphasia [42].
In PSP, cell loss in the SN affects both the pigmented
neurones of the pars compacta and non-pigmented neu-
rones in the pars reticulata, whereas neurones in the
medial nigra are relatively preserved [47]. In the present
study, neuronal loss was less severe in the ventrolateral
and dorsolateral subregions in PSP-CBS when compared
with PSP-RS (Figure 4). This regional difference may, in
part, influence the clinical features due to the resulting
selective damage to the dopaminergic and GABAergic
neuronal nigral projections [47].
Pyramidal signs were documented in half of our PSP-
CBS cases, but they were absent in our PSP-RS cohort.
Pyramidal signs are relatively uncommon in PSP and in
one series they were present in only one fifth of all patho-
logically confirmed PSP cases [2]. On the other hand, 60%
of pathologically confirmed CBD cases had pyramidal signs
[48]. In CBD, the pathological involvement of the primary
motor cortex including loss of Betz cells is a common
finding, explaining the presence of pyramidal signs
[44,48]. The common occurrence of pyramidal signs in
our PSP-CBS cohort can be explained by the abundant tau
pathology in the primary motor cortex, which was 12-fold
greater in PSP-CBS than in PSP-RS. There was also more
severe microglial pathology in the CST in PSP-CBS than in
PSP-RS. CST degeneration and significant tau pathology in
the motor cortex are also prominent in a group of ‘atypical’
PSP cases reported in the literature which sometimes clini-
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cally present with CBS [44,49]; however, whether these
cases should be classified as PSP has recently been ques-
tioned [50].
All PSP-CBS cases had received a final clinical diagno-
sis of CBS and they all had markedly asymmetrical cor-
tical and extrapyramidal features, including unilateral
limb clumsiness with a progressively maladroit and func-
tionally useless hand. In the past, the presence of marked
asymmetrical clinical signs would exclude the clinical
diagnosis of PSP, but this concept has been challenged in
recent years with the findings of clinicopathological
series confirming asymmetrical presentations in some
PSP variants [2,17]. Previously, a post mortem report of a
Japanese patient who had focal limb dystonia and levita-
tion revealed significantly more tau pathologies in the
frontal cortices, basal ganglia and brain stem in the con-
tralateral half brain than the ipsilateral half brain [51].
In our PSP-CBS cohort, there was numerically greater
total tau load and cortical tau load in five cases where
the contralateral half brain was available for evaluation
when compared with the other five cases where ipsilat-
eral half brain was examined. However, we cannot con-
clude if the tau load is greater in the clinically more
manifested hemisphere within an individual as only
half brains were used. Asymmetrical limb apraxia and
delayed initiation of horizontal saccades are clinical fea-
tures suggestive of underlying parietal lobe dysfunction
and are characteristic features of CBS [52]. We found
that regional tau load in the parietal white matter was
5-fold greater in PSP-CBS than in PSP-RS and that PSP-
CBS patients who had delayed initiation of horizontal
saccades also had greater regional tau load in the pari-
etal cortex and white matter.
Three patients had delayed initiation of horizontal sac-
cades and, interestingly, half of them also had VSGP in the
late stage of the illness, with involvement of downgaze,
a diagnostic prerequisite for the diagnosis of PSP-RS
[53,54]. VSGP is rare in CBD with classical CBS presenta-
tion (CBD-CBS), and was noted in only 18% of cases in the
Mayo Clinic series [14] and was not observed in the QSBB
series [17]. Six PSP-CBS patients had recurrent falls in the
first year of their illness, whereas early falls were less fre-
quent in CBD-CBS cases and were recorded in only 20%
and 18% in the QSBB and Mayo Clinic series, respectively
[14,17]. We postulate that early postural instability, falls
and supranuclear downgaze palsy in patients with CBS
are clinical clues which when present, suggest an under-
lying PSP pathology even though there are also signs of
CBS. Nevertheless, three cases in our PSP-CBS group
(cases 2, 7, 10) had a pure CBS presentation throughout
the disease course and did not have any tell-tale signs of
PSP. This is in concordance with our experience based on
clinicopathological evaluation of cases in the QSBB that
some pathologically confirmed PSP and CBD cases present
with a pure clinical syndrome such as CBS or RS irrespec-
tive of the underlying pathology, whereas some cases
manifest overlap clinical features such as RS or CBS at the
same time and occasionally, the clinical syndromes tem-
porally evolve from one to another throughout the disease
course as previously described by Kertesz et al. [9].
Data from transgenic animal studies indicate that
soluble rather than fully aggregated tau species may ulti-
mately be responsible for neuronal degeneration and cell
death [55]. However, the findings in this study support the
notion that neuronal and glial inclusions composed of
fibrillar pathological tau are useful and clinically valid
pathological markers of the underlying neurodegenera-
tive process. We have provided comprehensive evidence
that the topographical severity of tau pathology in PSP
is closely associated with its clinical manifestation
[5,6,11,30,42]. This is comparable to the findings in
Alzheimer’s disease where cognitive deficit shows a far
better correlation with tau lesions than with Ab plaques
[56] as well as in other primary tauopathies [44,57]. A
better understanding of the factors that influence the
selective pathological vulnerability in different PSP vari-
ants will provide further insights into the neurodegenera-
tive process underlying tauopathies.
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